OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
NASDAQ:OKYO$1.42+2.16%| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 52.48M shares outstanding
GBOKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort.
Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease.
Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Gary S. Jacob
Chief Development Officer & Director
Robert J. Dempsey
Chief Executive Officer & Executive Director
Flavio Mantelli
Chief Medical Officer
Keeren Shah
Chief Financial Officer
Employees
5
Country
GB
Sector
Healthcare
Website
okyopharma.com
Loading congressional disclosures…
based on 52.48M shares outstanding
GB30d Avg
68.88K
60d Avg
70.57K
90d Avg
92.76K
